An interventional study of Aerobic Exercise in Depression, sponsored by The Royal's Institute of Mental Health Research. Recruiting at 1 site in Canada. Open to participants aged 16 Years to 24 Years. Per ClinicalTrials.gov, last updated 2024-04-12.
Sponsored by The Royal's Institute of Mental Health Research · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 533 studies in Depression with a site in Canada — 107 open to participants now, 124 under way, 7 of them phase 3. Depression · Canada.
Among the 533 studies in Depression with a site in Canada, this one is the 341st largest by planned enrollment of the 488 interventional ones that give a count, is one of 35 that started in 2018, is one of 334 with no phase, reaches primary completion later than 23 of the 123 other live ones, and was the 291st registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →107 of the 533 studies in Depression with a site in Canada are open now. Recruiting first, the newest first:
Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
Eli Lilly and Company · Sites in Canada, United States, Australia and 12 more countries
Ages 18–75
University of Regina · Sites in Canada
Ages 18+
University of Toronto · Sites in Canada
Ages 18+
Lakshmi N Yatham · Sites in Canada
Ages 19–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 16 Years to 24 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
533 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 46 · Phase 3 55 · Phase 4 37
First in 1997; this study’s year is marked. 35 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 77 across the 488 interventional studies, 262 across the 45 observational. Of the 346 that completed or were terminated, 45 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 533 have an industry lead sponsor. The 10 most frequent:
The Royal's Institute of Mental Health Research is the lead sponsor of 7 studies on the registry; 6 are open to participants now.
The Royal's Institute of Mental Health Research has 2 studies filed under Depression — fewer than ten, so there is no comparison to draw.
35 of the studies in Depression with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06963021Phase 3Neurocrine BiosciencesNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | 2027-07 |
| NCT05543681IGC Pharma, LLCClinical Trial on Agitation in Alzheimer's Dementia | 2026-11 |
| NCT07313657Bruyère Health Research Institute.Improving Care and Mental Well-Being for Adults With Heart Failure | 2026-11-30 |
| NCT05543720University Health Network, TorontoEvaluation of Nurse-led Integrated Care of Complex Patients Facilitated By Telemonitoring: The SMaRT Study | 2026-12 |
| NCT06745349University of ReginaThe Sleep Course: An Online Sleep Intervention for Adults With Self-reported Sleep Difficulties | 2026-12 |
Add all 35 to your calendar (.ics) → With an account.
Among the 533 studies in Depression with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the effects of moderate vs. high intensity aerobic exercise, performed 3 times a week for 12 weeks under supervised conditions, on symptoms of depression, cognitive functioning and brain function in transitional aged youth (TAY: aged 16-24 years).
Rationale: Major depressive disorder (MDD) is a debilitating disorder characterized by persistent negative mood and a broad range of cognitive, and functional impairments. MDD is estimated to affect 4.4% of the global population, or over 300 million individuals, representing the single largest contributor to non-fatal health loss worldwide. Current treatment options are associated with sub-optimal rates of remission, with only 30-35% of MDD sufferers attaining remission with antidepressant drug monotherapy. One group for whom treatment selection is a particular challenge is transitional aged youth (TAY), encompassing the late teenage years into the early twenties. Although MDD onset typically occurs during this period - as high as 8.2% in Canadian TAY - the psychiatric community has only recently begun to recognize TAY as a unique psychiatric cohort in need of directed treatment. For example, although the use selective serotonin reuptake inhibitors (SSRIs) is the first-line treatment for MDD in adults, their utility in TAY is hampered by the possibility of increased suicidal ideation within this cohort. The need for alternative and tailored treatment options for TAY with MDD is therefore of paramount importance. Aerobic exercise (AE) has recently been recognized as one such intervention, with some reports showing outcomes comparable to pharmacological and psychotherapeutic approaches in adult populations. Few studies however, have investigated to what extent these findings extend to TAY. Further, there is little consensus as to which intensity level, or "dose", of AE offers the most benefit, which neural features underlie the putative benefits of AE in depressed TAY, and the impact on both psychosocial and cognitive processes.
Objectives: The primary objectives of this study are: 1) to determine the effects of moderate vs. high intensity AE on clinically-rated and subjective symptoms of MDD in TAY; and 2) to examine the psychosocial, cognitive, and neuromodulatory effects of these interventions.
Methods: This two-arm, randomized trial will recruit 40 TAY (16-24 yrs) with MDD/persistent depressive disorder (PDD) into one of two AE intensity groups: medium or high. Intensity is defined as a percentage of heart rate reserve (HRR) achieved during exercise, as outlined in the American College of Sports Medicine (ACSM) guidelines (moderate: 50-55% of HRR; N=20; high: 80-85% HRR; N=20). All participants will undergo supervised and guided AE intervention sessions (\~30min), three times per week, for twelve consecutive weeks. Pertinent clinical and psychosocial scores, as well as cardiac function (as assessed by maximal oxygen consumption [VO2max]), will be recorded pre-intervention (Week 0), mid-intervention (Week 6), and post-intervention (Week 12). Additionally, participants will undergo electroencephalographic (EEG) and functional magnetic resonance neuroimaging (fMRI) before and after the completion of AE intervention. Specifically, neural dynamics will be recorded at rest and during cognitive tasks engaging working memory (N-Back task) and response inhibition (Flanker task) - cognitive abilities, which have been shown to be impaired in MDD in TAY. Both clinical/psychosocial and neuroimaging outcomes will be compared using time as the within-group, and intervention type as between-group factors.
Hypotheses: The investigators expect a significant reduction in depression symptoms post (vs. pre) intervention and, based on preliminary evidence in adults, a greater reduction may emerge in those participating in the high (vs. moderate) intensity AE. Further, the investigators expect changes in fMRI profiles from pre- to post-intervention (showing normalization of brain activity and connectivity profiles); the same is true of EEG/event-related potential (ERP) features. They also expect a positive relation between VO2max and brain-based changes.
Significance: Findings from this project will help guide future large-scale investigations of AE as a potential treatment for TAY by clarifying the relation between changes to physical indices, depressive symptoms and neural profiles. Importantly, identifying the brain features modulated by AE will broaden our understanding of the neurobiological markers underlying depressive states, allowing for targeted therapeutic approaches and better outcomes for TAY suffering from MDD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aerobic exercise maintained for 30 minutes at 50-55% of each participant's individual heart rate reserve (HRRes).
Behavioral: Aerobic Exercise
Aerobic exercise maintained for 30 minutes at 80-85% of each participant's individual heart rate reserve (HRRes).
Behavioral: Aerobic Exercise
Thrice-weekly aerobic exercise sessions lasting \~45 minutes, for 12 consecutive weeks.
Changes in clinician-rated depression-related symptoms
Changes in depressive symptoms as measured by the Hamilton Depression Rating Scale (HDRS) \& Montgomery-Asberg Depression Rating Scale (MADRS).
Time frame: Baseline, Mid-Intervention (6 weeks), Post-Intervention (12 weeks)
Changes in self-reported depression-related symptoms
Changes in depressive symptoms as measured by the Beck Depression Inventory (BDI; self-reported)
Time frame: Baseline, Mid-Intervention (6 weeks), Post-Intervention (12 weeks), 3-month follow-up, 6-month follow-up
Feasibility of moderate & high intensity aerobic exercise as a treatment regimen.
Operationalized as: a) recruitment and randomization - the number of individuals who are successfully screened into the study, and the number of individuals randomized to each treatment following successful screening, respectively, over a 24 month period; and b) retention - the extent to which participants remain enrolled in the study, ie the number of participants who complete follow-up testing.
Time frame: Every 24 months from recruitment initiation until study completion
Adherence to moderate & high intensity exercise regimens as prescribed
The number of exercise session attended by each participant (out of the total 36 sessions prescribed).
Time frame: Assessed per participant, through study completion
Compliance to moderate & high intensity exercise regimens as prescribed
The percentage of time, per session, that a participant spends within his/her prescribed heart rate zone.
Time frame: Assessed per participant, through study completion
Changes in electrocortical-indexed brain activity profiles
Assessed via EEG during computerized tasks of attention/inhibition and working memory.
Time frame: Baseline & Post-Intervention (12 weeks)
Changes to neuroimaging-indexed brain activity profiles
Assessed via fMRI during computerized tasks of attention/inhibition and working memory.
Time frame: Baseline & Post-Intervention (12 weeks)
Changes to self-esteem
Assessed with the Rosenberg Self-Esteem Scale, a 10-item self-report questionnaire.
Time frame: Baseline, Mid-Intervention (6 weeks), Post-Intervention (12 weeks)
Changes in self-mastery
Assessed with Perlin/Schooler's Mastery Scale a 7-item self-report questionnaire.
Time frame: Baseline, Mid-Intervention (6 weeks), Post-Intervention (12 weeks)
Changes in daily functioning
Assessed via the Columbia Impairment Scale, a 13-item self-report questionnaire.
Time frame: Baseline, Mid-Intervention (6 weeks), Post-Intervention (12 weeks)
Changes in cognitive function
Assessed via the NIH Cognitive Toolbox; a cognitive battery consisting of 7 distinct computerized tasks assessing multiple cognitive constructs. Performance on each task is combined to produce a composite score.
Time frame: Baseline, Mid-Intervention (6 weeks), Post-Intervention (12 weeks)
Started Aug 2018 (actual). Primary completion is estimated for Sep 2025, 84 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 84 months is above that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Royal's Institute of Mental Health Research